Marek Buczek
Neurology · Cleveland, OHNPI 1093748113
Payments from drug & device makers
Across 190 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$813
- Novartis$402
- Lilly USA, LLC$312
- Biogen$148
- Amgen$123
- Sanofi$102
- plus $949 from 22 others
What the payments were for
- Speaking & faculty fees$171%
- Food & beverage$2,79598%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $813 |
| Novartis | 38 | $402 |
| Lilly USA, LLC | 20 | $312 |
| Biogen | 13 | $148 |
| Amgen(2 entities) | 7 | $123 |
| Sanofi | 6 | $102 |
| Teva Pharmaceuticals USA, Inc. | 6 | $100 |
| AstraZeneca(2 entities) | 5 | $90 |
| Genentech USA, Inc. | 5 | $85 |
| CSL Behring | 5 | $81 |
| Biohaven Pharmaceuticals, Inc. | 4 | $76 |
| EMD Serono, Inc. | 4 | $70 |
| Lundbeck LLC | 4 | $69 |
| Arbor Pharmaceuticals, Inc. | 4 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| UCB, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Amneal Pharmaceuticals LLC | 2 | $25 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Adamas Pharmaceuticals, Inc. | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Si-bone, Inc. | 1 | $16 |
| Aquestive Therapeutics, Inc. | 1 | $16 |
| Promius Pharma LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $12 |
How this compares
$2,848 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 25 | $352 |
| Gabapentin | 16 | $224 |
| Donepezil Hcl | 25 | $106 |
| Topiramate | 22 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Upsher-smith Laboratories LLCTopiramate | $12 | $10322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 702 neurology providers in Ohio.
Other neurology in Cleveland
- Robert BermelCleveland$6.4M
- Jeffrey CohenCleveland$3.1M
- Yuebing LiCleveland$1.4M
- Devon ConwayCleveland$1.3M
- Robert FoxCleveland$1.3M
- Glen StevensCleveland$1.1M
- Hubert FernandezCleveland$1.1M
- Hesham AbboudCleveland$1.1M
- Michal GostkowskiCleveland$850K
- Daniel OntanedaCleveland$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.